QUANTITATIVE PET PARAMETERS PREDICTS OUTCOME IN PATIENTS WITH HODGKIN'S LYMPHOMA

EHA Library, I. Kriachok, 180903

BIOMARKER ANALYSIS OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH IBRUTINIB IN THE PHASE 2 DAWN STUDY

EHA Library, Gilles Salles, 180905

DYNAMO: THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA IN A PHASE 2 STUDY

EHA Library, Pier Luigi Zinzani, 180906

WALDENSTROM MACROGLOBULINEMIA: UK REAL WORLD EXPERIENCE

EHA Library, Dima El-Sharkawi, 180908

CLINICAL CHARACTERISTICS AND LONG-TERM RESULTS OF TREATMENT OF INDOLENT NON-HODGKIN'S LYMPHOMA ASSOCIATED WITH HEPATITIS C (IL + C)

EHA Library, sergey lepkov, 180909

90Y-IBRITUMOMAB-TIUXETAN AS FIRST-LINE CONSOLIDATION IN COMPLETE RESPONSE FOLLICULAR LYMPHOMA PATIENTS. SINGLE CENTER ANALYSIS AFTER SIX YEARS MEDIAN FOLLOW-UP.

EHA Library, Marcio Andrade-Campos, 180910

ASSESSING RISK OVER TIME IN PATIENTS WITH SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA (WM). A STUDY ON 114 PATIENTS (PTS).

EHA Library, pierre morel, 180911

TIME TO NEXT TREATMENT ANALYSIS FOR EARLY AND ADVANCED STAGES OF MYCOSIS FUNGOIDES /SEZARY SYNDROME TREATED WITH BEXAROTENE AND PUVA IN COMBINATION

EHA Library, Serena Rupoli, 180912

PERIPHERAL BLOOD INVOLVEMENT IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA: CLINICAL-BIOLOGICAL CHARACTERISTICS AND PROGNOSTIC IMPACT

EHA Library, Alfredo Rivas-Delgado, 180913

TREATMENT PATTERNS OF PATIENTS WITH FOLLICULAR LYMPHOMA IN A LARGE US-INSURED DATABASE FROM 2010 TO 2014

EHA Library, Maneesha Mehra, 180914

A PHASE 1 STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS (PK) OF VENETOCLAX (VEN) IN JAPANESE PATIENTS (PTS) WITH NON-HODGKIN LYMPHOMA (NHL) AND MULTIPLE MYELOMA (MM)

EHA Library, Kazuhito Yamamoto, 180915

A SIMPLIFIED APPROACH IN THE ASSESSMENT OF T-CELL CLONALITY BY FLOW CYTOMETRY

EHA Library, Mary Sartor, 180916

A HIGHER AMOUNT OF LILOTOMAB PRE-DOSING INCREASES THE ACTIVITY-ADJUSTED AUC AND HAS A PROTECTIVE EFFECT AGAINST MYELOSUPPRESSION OF LUTETIUM (177LU)-LILOTOMAB SATETRAXETAN IN INDOLENT NHL PATIENTS

EHA Library, Arne Kolstad MD,, 180917

PHARMACOKINETICS AND TOLERABILITY OF OFATUMUMAB AND BENDAMUSTINE IN PATIENTS WITH INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA

EHA Library, Andres Forero-Torres, 180918

ASSESSMENT OF INTERNATIONAL CONSENSUS GROUP FOR HEMATOLOGY (ICGH) SMEAR REVIEW RULES FOR AUTOMATED PLATFORMS IN THE DETECTION OF MALARIA

EHA Library, Jenifer Vaughan, 180919

A PROSPECTIVE MULTICENTER STUDY OF CANDIDEMIA IN NEUTROPENIC PATIENTS WITH HEMATOLOGICAL DISEASES: INCIDENCE, RISK FACTOR AND OUTCOMES

EHA Library, Chen Hua Yan, 180920

BRONCHOALVEOLAR LAVAGE AS SYSTEMATIC APPROACH FOR EARLY DIAGNOSIS OF LUNG INFILTRATES AND INVASIVE PULMONARY ASPERGILLOSIS IN HEMATOLOGIC PATIENTS: A PROSPECTIVE SINGLE INSTITUTION STUDY

EHA Library, Francesco Marchesi, 180921

ESCAPE DRUG-RESISTANT INFECTIONS IN HEMATOLOGICAL MALIGNANCIES. DARE TO REVIEW!

EHA Library, Cesar Gentille Sanchez, 180922

PROPOSED PEGIFLGRASTIM BIOSIMILAR CHS-1701 DEMONSTRATES PHARMACOKINETIC AND PHARMACODYNAMIC SIMILARITY TO MARKETED PEGFILGRASTIM IN A RAT NEUTROPENIA MODEL AND IN HEALTHY SUBJECTS

EHA Library, Paula OConnor, 180923

A RETROSPECTIVE REVIEW IDENTIFYING RESISTANT MICROBIAL STRAINS, ANTIMICROBIAL SENSITIVITIES AND RISK STRATIFICATION OF FIRST LINE ANTIBIOTIC USE IN ADULT CANCER PATIENTS WITH NEUTROPENIC SEPSIS

EHA Library, Akila Danga, 180924

PRELIMINARY RESULTS FROM A LONG-TERM REPEAT DOSE TOXICITY AND TOXICOKINETIC STUDY OF ANF-RHO, A NOVEL ANTI-NEUTROPENIC FACTOR

EHA Library, Hemant Misra, 180925

USE OF MICAFUNGIN IN PROPHYLAXIS IN ONCO-HEMATOLOGY : RESULTS OF AN OBSERVATIONAL, MULTICENTER, PROSPECTIVE FRENCH STUDY (OLYMPE)

EHA Library, Jean El Cheikh, 180926

OUTBREAK OF MULTI-DRUG RESISTANT PSEUDOMONAS AERUGINOSA (MPA) IN A HAEMATOLOGY WARD (HW): MANAGEMENT AND INFECTION CONTROL MEASURES

EHA Library, DANIELE ARMIENTO, 180927

MONITORING VORICONAZOLE PHARMACOGENOMICS AND PLASMA CONCENTRATIONS IN THE TREATMENT AND PREVENTION OF INVASIVE FUNGAL DISEASE FOR HEMATOLOGICAL PATIENTS------A SINGLE CENTER EXPERIENCE

EHA Library, Xiaowen Tang, 180928

BACTEREMIA AND SEPSIS FOLLOWING INTENSIVE CHEMOTHERAPY OF ADULT ONCOHEMATOLOGICAL PATIENTS

EHA Library, Stanislav Bessmeltsev, 180929

GLYCOSYLATED FERRITIN MEASURING SIGNIFICANCE FOR SECONDARY HEMOPHAGOCYTIC SYNDROME DIAGNOSTICS

EHA Library, Vsevolod Potapenko, 180930

SERUM HEPCIDIN QUANTIFICATION IN INFLAMMATORY BOWEL DISEASES

EHA Library, Victor Manolov, 180931

MUTATIONS IN YARS2 CAUSE CONGENITAL SIDEROBLASTIC ANEMIA WITHOUT SHOWING EVIDENCES OF MYOPATHY AND LACTIC ACIDOSIS

EHA Library, Beatriz Cadenas, 180932

IRON CHELATION DATA OF CONGENITAL DYSERYTHROPOIETIC ANEMIA PATIENTS: A SINGLE CENTER EXPERIENCE

EHA Library, Mualla Cetin, 180933

ORAL IRON CHELATION FOR TREATMENT OF HEREDITARY HEMOCHROMATOSIS IN CHILDREN

EHA Library, Maria Moraki, 180934

NEUTROPHIL HYPERSEGMENTATION IN ADULTS WITH IRON DEFICIENCY: A CASE-CONTROL STUDY

EHA Library, Isilnokta Erdogan, 180935

M-TOR INHIBITORS-ASSOCIATED MICROCYTIC ANEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.

EHA Library, Angel F Remacha, 180936

IRON METABOLISM IN PATIENTS WITH PAROXISMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Elena Lukina, 180937

ORAL IRON ELEVATES SERUM IRON AND CONSEQUENTLY CHANGES IRON DISTRIBUTION IN LIVER AND ERYTHROCYTES

EHA Library, Yukari Tezuka, 180938

DEFERASIROX FOR SEVERE ANAEMIAS IN YOUNG CHILDREN

EHA Library, Arief Gunawan, 180939

MONITORING ORAL IRON THERAPY IN CHILDREN WITH IRON DEFICIENCY ANEMIA. AN OBSERVATIONAL, PROSPECTIVE, MULTICENTRIC STUDY

EHA Library, Giovanna Russo, 180940

AN INVESTIGATION ABOUT WEIGHT GAIN WITH TREATMENT OF IRON DEFICIENCY ANEMIA: CHANGES OF GHRELIN AND HEPCIDIN LEVELS WITH TREATMENT

EHA Library, Birgul Onec, 180941

SOMATIC MUTATION DYNAMICS IN HIGH-RISK MDS PATIENTS TREATED WITH AZACITIDINE IDENTIFIED VIA SERIAL SAMPLING

EHA Library, Tomas Stopka, 180942

WHOLE GENOME MBD-SEQ REVEALS DIFFERENT CPG METHYLATION PATTERNS IN AZACYTIDINE-TREATED JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) PATIENTS

EHA Library, Pier Paolo Leoncini, 180943

RESPONSE MONITORING IN MDS WITH DEL(5Q) USING DIFFERENT FLOW CYTOMETRIC (FCM)-SCORES IN COMPARISON TO CYTOGENETICS – AN ELNET IMDS-FLOW EXPERIENCE

EHA Library, Uta OELSCHLAEGEL, 180944

EVALUATION OF MUTATIONS AT RELAPSE IN MYELODYSPLASTIC SYNDROME PATIENTS RECEIVING ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Monica Cabrero, 180945

RIGOSERTIB COMBINED WITH AZACITIDINE EPIGENETICALLY MODULATES CHROMATIN AND HEMATOPOIETIC STEM CELL POPULATIONS IN THE MYELODYSPLASTIC SYNDROME (MDS)

EHA Library, Lewis Silverman, 180946

UNEXPLAINED CYTOPENIAS IN HOSPITAL : INDICATIONS AND BENEFITS OF NEXT-GENERATION SEQUENCING

EHA Library, David Beauvais, 180947

RESISTANCE TO AZACITIDINE IS DETERMINED AT CELLULAR LEVEL BY LOWER EXPRESSION OF NUCLEOSIDE ACTIVATING ENZYMES UCK1 AND UCK2

EHA Library, Valeria SANTINI, 180949

FAMILIAL TIN2 N-TERMINAL LOSS OF FUNCTION MUTATION IN TELOMERE SYNDROME

EHA Library, Danika Di Giacomo, 180950

FUNCTIONAL EXPRESSION OF TIM-3 AND CLINICAL SIGNIFICANCE OF PLASMA GALECTIN-9 LEVELS IN MYELODYSPLASTIC SYNDROMES

EHA Library, Toshio Asayama, 180951

PROGNOSTIC SIGNIFICANCE OF GENE MUTATIONS IN MDS DEPENDS ON THE LOCI OF GENE VARIANCES

EHA Library, Temenuzhka Boneva, 180952

SUPPRESSION OF DNA METHYLTRANSFERASE ENZYMES BY A NOVEL HYPOMETHYLATING AGENT, SGI-1027, IN AZACITIDINE- AND DECITABINE-RESISTANT CELL LINES

EHA Library, Eun-Hye HUR, 180953

MECHANISTIC HIGHLIGHTS OF IMPROVED ERYTHROPOIESIS WITH A LOW DOSE OF DEFERASIROX IN LOW RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Mathieu Meunier, 180954

EVALUATING ERYTHROBLAST PAS POSITIVITY IN THE DIAGNOSTIC APPROACH OF MYELODYSPLASTIC SYNDROME

EHA Library, Rosangela Invernizzi, 180955

A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Uwe Platzbecker, 180956

PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY OF SINTRA-REV CLINICAL TRIAL, LENALIDOMIDE VS PLACEBO PHASE 3 STUDY IN LOW/INT-1 MDS PATIENTS WITH DEL(5Q) AND TRANSFUSION INDEPENDENCY.

EHA Library, Felix Lopez Cadenas, 180957

MYELODYSPLASIA-RELATED MORTALITY REMAINS THE MAIN CAUSE OF DEATH ALONG DIFFERENT GROUPS OF RISKS: AN ANALYSIS FROM MDS ARGENTINEAN STUDY GROUP

EHA Library, Alicia Enrico, 180958

PROSPECTIVE STUDY OF FLOW CYTOMETRY OF BONE MARROW IN 105 CONSECUTIVE PATIENTS WITH CYTOPENIA AND SUSPICION OF MYELODYSPLASTIC SYNDROME: STRONG CORRELATION WITH RISK OF AML-EVOLUTION AND SURVIVAL

EHA Library, Fernando Marco De Lucas, 180959

ECONOMIC IMPACT AND HEALTHCARE UTILIZATION IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) – A CLAIMS DATABASE STUDY

EHA Library, Jill Bell, 180960

INTRAVENOUS IMMUNOGLOBULIN IS AN EFFECTIVE TREATMENT FOR CYTOPENIAS ASSOCIATED TO CIRCULATING T-CELL CLONES IN MYELODYSPLASTIC SYNDROMES

EHA Library, Lewis Silverman, 180961

DEVELOPMENT AND EXTERNAL VALIDATION OF A NEW PATIENT-CENTERED PROGNOSTIC INDEX FOR PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES

EHA Library, Fabio Efficace, 180962

PROGNOSTIC AND THERAPEUTIC IMPLICATIONS OF SIGNIFICANT MARROW FIBROSIS IN COMBINATION WITH P53 OVER-EXPRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME: A SINGLE CENTRE STUDY

EHA Library, Emma Groarke, 180963

FACS PURIFICATION OF BLAST CELLS IN MDS IMPROVES THE FISH DETECTION RATE FOR DEL(5Q) AND DEL(20Q), BUT NOT FOR DEL(7Q) OR T8

EHA Library, Marta Pereira, 180964

COUNTING BONE MARROW BLASTS AS A PERCENTAGE OF NON-ERYTHROID CELLS PROVIDES SUPERIOR RISK STRATIFICATION FOR MDS PATIENTS WITH ERYTHROID PREDOMINANCE

EHA Library, Aining Sun, 180965

SUCCESSFUL TREATMENT WITH DANAZOL FOR MYELODYSPLASTIC SYNDROMES AND APLASTIC ANEMIA REFRACTORY OR INELIGIBLE TO STANDARD THERAPY

EHA Library, Anna Maria Pelizzari, 180966

SURVIVAL OUTCOMES IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) – A CLAIMS DATABASE STUDY

EHA Library, Jill Bell, 180967

DOSE-CONFIRMATION PK/PD STUDY OF ORAL ASTX727, A COMBINATION OF ORAL DECITABINE WITH A CYTIDINE DEAMINASE INHIBITOR (CDAI) E7727, IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Mohammad Azab, 180968

FACTORS PREDICTIVE FOR INFECTION IN PATIENTS WITH HIGHER- RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA AND ACUTE MYELOID LEUKEMIA TREATED WITH AZACITIDINE.

EHA Library, Krzysztof Madry, 180969

OVERALL SURVIVAL, INITIAL TREATMENT AND TREATMENT DURATION OF PATIENTS WITH MYELODYSPLASTIC SYNDROME, A DETAILED POPULATION BASED STUDY

EHA Library, Hanne Rozema, 180970

DANAZOL TREATMENT FOR THROMBOCYTOPENIA IN LOWER-RISK MYELODYSPLASTIC SYNDROMES: A REAL LIFE EXPERIENCE

EHA Library, Emanuele Ravano, 180971

TREATMENT PATTERNS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) – A CLAIMS DATABASE STUDY

EHA Library, Jill Bell, 180972

APPRECI8: A PIPELINE FOR PRECISE VARIANT CALLING INTEGRATING 8 TOOLS

EHA Library, Sarah Sandmann, 180973

COMPARISON OF ADMINISTRATION OF HYPOMETHYLATING AGENTS WITH EFFICIENCY OF ALLOGENEIC SCT IN ELDERLY PATIENTS WITH ADVANCED MDS

EHA Library, Jaroslav Cermak, 180974

A MULTICENTER, OPEN-LABEL, PHASE I CLINICAL STUDY: SAFETY, EFFICACY, AND PHARMACOKINETICS OF ORAL RIGOSERTIB IN JAPANESE PATIENTS WITH RECURRENT/RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES

EHA Library, Kenichi Ishizawa, 180975

NON-OVERLAPPING PROMOTER AND SUPERENHANCER DRIVEN PROCESSES SUPPORT MYELOMA CELL GROWTH AND SURVIVAL VIA DISTINCT REGULATORY AXES

EHA Library, Mariateresa Fulciniti, 180976

ANALYSIS OF THE GENOMIC LANDSCAPE OF MULTIPLE MYELOMA HIGHLIGHTS NOVEL CANDIDATE PROGNOSTIC MARKERS AND DISEASE SUBGROUPS

EHA Library, Niccolò Bolli, 180977

A NOVEL METHOD FOR GENOME-WIDE COPY NUMBER ASSESSMENT FROM TARGETED SEQUENCING DATA AND CLINICAL APPLICATION IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Georgie Ryland, 180978

THE MULTIPLE MYELOMA GENOME PROJECT: DEVELOPMENT OF A MOLECULAR SEGMENTATION STRATEGY FOR RISK STRATIFICATION OF MULTIPLE MYELOMA

EHA Library, Gareth Morgan, 180979

ALVOCIDIB SYNERGIZES WITH VENETOCLAX IN PRECLINICAL MODELS OF MULTIPLE MYELOMA

EHA Library, Steven Warner, 180980

NOVEL COMPOUND, OSSL_325096, INDUCES APOPTOSIS IN MULTIPLE MYELOMA CELLS THROUGH VCP INHIBITION

EHA Library, Nao Nishimura, 180981

A NOVEL PREDICTIVE MODEL COMBINING LINCRNAS AND PROTEIN CODING GENES IN MULTIPLE MYELOMA

EHA Library, Mehmet Samur, 180982

DYNAMIC IMMUNOHISTOCHEMICAL EVALUATION OF MARROW MICROENVIRONMENT MODIFICATIONS IN PATIENTS WITH SMOLDERING MYELOMA

EHA Library, Alberto Mussetti, 180983

IMMUNE CELL PROFILING IN BONE MARROW OF MYELOMA PATIENTS POST AUTOLOGUS STEM CELL TRANSPLANT SHOWS PRESENCE OF CYTOTOXIC CD4 AND CD8 CELLS, WITH PROMINENT LAG-3 EXPRESSION AND OTHER CHECKPOINT MARKERS

EHA Library, Nouf Alrasheed, 180984

INHIBITION OF EXTRACELLULAR VESICLE SECRETION INDUCES APOPTOSIS OF BONE MARROW STROMAL CELLS: TOWARDS SOIL-TARGETED THERAPY IN MULTIPLE MYELOMA

EHA Library, Tomohiro UMEZU, 180985

SINGLE-NUCLEOTIDE POLYMORPHISM IN THE PBK GENE IS CLOSELY ASSOCIATED WITH MYELOMA CELL PROLIFERATION.

EHA Library, Ichiro Hanamura, 180986

THE HISTONE METHYLTRANSFERASES G9A/GLP REPRESENT NEW PROMISING TARGETS FOR THE TREATMENT OF MULTIPLE MYELOMA

EHA Library, Eva De Smedt, 180987

CYTOTOXIC LYMPHOCYTES IN NEWLY DIAGNOSED MYELOMA HAVE REVERSIBLE FUNCTIONAL AND PHENOTYPIC ABNORMALITIES THAT MAY OFFER THERAPUTIC OPPORTUNITIES

EHA Library, Frances Seymour, 180988

P53-RESTORING SMALL MOLECULE CP-31398 INDUCES APOPTOSIS VIA INDUCTION OF REACTIVE OXIDATIVE SPECIES IN HUMAN MULTIPLE MYELOMA

EHA Library, Yohei Arihara, 180989

TUMOR MICROENVIRONMET TRANSFORMATION FROM MGUS TO MYELOMA IS ASSOCIATED WITH PRO-TUMORAL ACTIVATION OF MESENCHYMAL STROMAL CELLS (MSC)

EHA Library, Cesarina Giallongo, 180990

LONG TERM CR MULTIPLE MYELOMA PATIENTS STUDIED WITH NEXT GENERATION FLOW SHOW PREDOMINANTLY CURED VS MGUS-LIKE MINIMAL RESIDUAL DISEASE PATTERNS: A STUDY OF THE GTMM-TUSCAN GROUP FOR MULTIPLE MYELOMA

EHA Library, Alessandro Gozzetti, 180991

THE NOTCH PATHWAY IN THE INTERPLAY BETWEEN MYELOMA CELLS AND ENDOTHELIUM IN THE BONE MARROW NICHE

EHA Library, Maria Teresa Palano, 180992

MIR-101-3P REGULATES BONE MARROW STROMA-INDUCED DRUG RESISTANCE IN MULTIPLE MYELOMA CELLS BY TARGETING SURVIVIN AND MODULATING CELL-CELL ADHESION

EHA Library, Jahangir Abdi, 180993

ARQ-197, A SMALL-MOLECULE INHIBITOR OF C-MET, REDUCES TUMOUR BURDEN AND PREVENTS TUMOUR-ASSOCIATED BONE DISEASE IN A MURINE MODEL OF MYELOMA

EHA Library, Andrew Chantry, 180994

THE GENETIC LANDSCAPE OF THE MURINE 5T MODELS FOR MULTIPLE MYELOMA

EHA Library, Ken Maes, 180996

CHARACTERIZING THE CONTRIBUTION OF BONE MARROW STROMA-DERIVED IL-6 TO MYELOMA GROWTH AND RESISTANCE

EHA Library, Tamas Csikos, 180997

THE PAN-PIM KINASE INHIBITOR, PIM447, POTENTLY SYNERGIZES WITH POMALIDOMIDE PLUS DEXAMETHASONE IN PRECLINICAL IN VITRO AND IN VIVO MODELS OF MULTIPLE MYELOMA

EHA Library, Teresa Paíno, 180998

EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA.

EHA Library, Nicola Giuliani, 180999

TRIM33 IS A POTENTIAL TUMOR SUPPRESSOR IN MULTIPLE MYELOMA

EHA Library, Cliona , 181000

LONG NON-CODING RNAS EXPRESSION HETEROGENEITY AND FUNCTIONAL INVOLVEMENT IN MULTIPLE MYELOMA

EHA Library, Arantxa Carrasco, 181001

ROLE OF EPHA3 IN MULTIPLE MYELOMA: A PERSPECTIVE FOR A NOVEL TARGET THERAPY?

EHA Library, FRANCESCO LA ROCCA, 181002

PROGNOSTIC SIGNIFICANCE OF AMP1Q21 IN MULTIPLE MYELOMA

EHA Library, Tatiana Abramova, 181003

ADAPTIVE IMMUNE RESPONSE IN PLASMA CELL DYSCRASIAS: IMMUNE PROFILING AND DETERMINATION OF CIRCULATING B CELL LEVELS AS A SURROGATE ASSAY FOR BONE MARROW TESTING

EHA Library, Stephen Drain, 181004

NOVEL MONOCLONAL ANTIBODY THERAPY TARGETING CD26 IN MULTIPLE MYELOMA

EHA Library, Hiroko Nishida, 181005

KYNURENINE INHIBITS T-CELLS THROUGH THE ARYL HYDROCARBON RECEPTOR AT IDO-POSITIVE TUMOR MICROENVIRONMENT

EHA Library, Soranobu Ninomiya, 181006